Laser Treatment for Psoriasis — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Laser treatment for psoriasis uses concentrated light energy delivered directly to psoriatic plaques to suppress the aberrant immune activity driving the characteristic keratinocyte hyperproliferation of the skin condition. The most widely used device is the 308 nm excimer laser — a xenon chloride laser emitting ultraviolet B (UVB) radiation at the same wavelength as narrowband UVB phototherapy, but with the ability to deliver much higher fluences (doses) to individual plaques without exposing surrounding healthy skin to UV radiation. This targeted delivery allows the use of substantially higher doses per session, achieving plaque clearance in fewer treatments than conventional phototherapy cabinets. Pulsed dye laser (PDL, 585–595 nm) targets the dermal vasculature feeding psoriatic plaques and is used as an adjunct or alternative for thin or scalp plaques. Low-level laser therapy (LLLT) with red or near-infrared wavelengths is also used in some dermatology units for scalp and nail psoriasis. All laser approaches are performed by dermatologists or trained laser technicians in a clinical setting. They represent a targeted phototherapy option for localised plaque psoriasis (affecting <10% body surface area), scalp psoriasis, and psoriasis at anatomically difficult sites such as the elbows, knees, and palms, where conventional phototherapy cabinets are less practical.

Laser therapy is indicated for patients with localised plaque psoriasis (typically involving less than 10% body surface area) who have not responded adequately to topical therapies including potent corticosteroids (betamethasone valerate 0.1%, clobetasol propionate 0.05%), vitamin D analogues (calcipotriol, calcitriol), and coal tar preparations, or who have thick, recalcitrant plaques at specific sites. Primary indications include: chronic plaque psoriasis at elbows, knees, shins, and scalp that is resistant to topical treatment; psoriasis in areas where topical steroids cannot be used long-term due to skin atrophy risk (face, flexures, genitalia); palmoplantar psoriasis causing significant functional disability; scalp psoriasis with thick adherent scale not responding to medicated shampoos (ketoconazole, coal tar, salicylic acid); nail psoriasis causing pain or functional impairment; and localised psoriasis where patients prefer a phototherapy approach to avoid systemic drug side effects. Contraindications include photosensitive conditions (lupus erythematosus, porphyria, xeroderma pigmentosum), concurrent use of photosensitising medications (doxycycline, hydrochlorothiazide, St John's wort), history of photosensitive skin cancers, and patients on immunosuppressive therapy that may interact with UV-induced immune modulation.

Excimer laser treatment sessions begin with assessment of the psoriasis plaques — measuring surface area, thickness, and erythema (PASI or mPASI score). The patient's skin type (Fitzpatrick classification I–VI) determines the initial UV dose (minimum erythema dose, MED), established from a prior test patch or published treatment protocols. The laser handpiece is held perpendicular to the skin surface at 1–2 cm distance and activated for a calculated time (typically 1–10 seconds per plaque area) to deliver the target UV dose in millijoules per square centimetre (typically 200–3000 mJ/cm² depending on treatment stage and skin type). Patients wear protective laser goggles throughout. The handpiece delivers a spot of approximately 30 × 30 mm per activation, requiring adjacent overlapping spots to cover larger plaques. Sessions typically last 15–30 minutes depending on the number and size of plaques. Treatment is given 2–3 times per week with doses escalated progressively by 10–15% per session if there is no erythema (redness) response, or maintained or reduced if erythema is present. A typical clearance course requires 10–20 sessions over 5–10 weeks. Maintenance therapy with monthly sessions prolongs remission for many patients. Pulsed dye laser (PDL) sessions for scalp or vascular psoriasis use a chilled probe or cryogen spray to protect the epidermis while targeting dermal vessels.

Excimer laser therapy achieves clinically significant plaque clearance (PASI-75 — 75% reduction in plaque severity score) in 75–90% of patients with localised plaque psoriasis after 10–20 sessions, superior to conventional narrowband UVB phototherapy which requires 20–36 sessions for equivalent outcomes. Remission (maintained improvement) lasts 3–6 months on average after a course of treatment; maintenance therapy extends remission. The primary advantage of excimer laser over phototherapy cabinets is targeted UV delivery to affected plaques only, reducing total body UV exposure and thereby the long-term cumulative risk of skin photoaging and skin cancer. This makes repeated treatment courses more acceptable compared to whole-body phototherapy. Patient satisfaction rates exceed 80% in published dermatology clinic series. For palmoplantar psoriasis — one of the most treatment-resistant subtypes — excimer laser combined with calcipotriol cream achieves 60–75% improvement, substantially better than topical therapy alone. Pulsed dye laser improves nail psoriasis (subungual hyperkeratosis, onycholysis) in 70–80% of nail units treated at 3–6 sessions, with durable improvement lasting 6–12 months.

Laser treatment for psoriasis is well tolerated with side effects predominantly related to controlled UV dose delivery. Erythema (redness) at treated sites lasting 24–48 hours is an expected and dose-dependent response indicating adequate UV delivery; severe blistering from over-treatment (erythema grade 3–4) requires session skipping and dose reduction. Hyperpigmentation (darkening) at treated plaque sites occurs in 10–20% of patients, particularly in skin types IV–VI, and is usually temporary (resolving in 3–6 months) but may be prolonged. Blistering is uncommon with calibrated treatment protocols but possible at thin-skinned sites (face, flexures) or when plaques thin rapidly with treatment. Burning or stinging sensation during treatment is common but brief. Long-term UV exposure risks — cumulative photoaging (premature wrinkles, skin texture changes) and theoretical increased skin cancer risk — are substantially lower with excimer laser (targeted delivery) compared to whole-body phototherapy. Koebner phenomenon (new psoriatic plaques appearing at sites of skin injury) may be triggered by excessive laser fluences. Eye protection is mandatory during all laser sessions to prevent UV-induced photokeratitis (inflammation of the cornea) and cataract risk. Excimer laser does not carry the risk of systemic immunosuppression side effects seen with biologic or systemic therapies.

Recovery after individual excimer laser sessions requires no downtime. Most patients return immediately to normal activities including work and driving. Treated skin may appear slightly red for 24–48 hours; cool compresses and moisturising emollients (such as Diprobase, Doublebase, or equivalent) soothe post-session erythema. Patients should avoid additional sun exposure to treated areas on treatment days and apply SPF 30+ sunscreen if the treated areas will be exposed. Topical corticosteroids or vitamin D analogues may continue to be used on non-treatment days as part of a combined regime. Between sessions, patients are advised to moisturise twice daily to prevent plaque scale build-up that reduces UV penetration. Following completion of a clearance course, maintenance sessions every 4–8 weeks prolong remission and reduce the frequency of full retreatment courses. The dermatology team reviews the PASI score at weeks 5–10 to assess treatment response and adjust the ongoing management plan accordingly. Patients with satisfactory responses may be eligible for continued laser maintenance, switched to a topical maintenance regime, or referred for systemic therapy (methotrexate, acitretin, biologics) if disease is not adequately controlled long-term with phototherapy alone.